Modality
Peptide
MOA
EZH2i
Target
TYK2
Pathway
Proteasome
Psoriasis
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Aug 2027
Phase 2Current
NCT04288211
670 pts·Psoriasis
2019-08→2027-08·Terminated
NCT05304450
2,764 pts·Psoriasis
2025-06→2025-01·Completed
3,434 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-201.2y agoPh2 Data· Psoriasis
2027-08-211.4y awayPh2 Data· Psoriasis
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2025-01-20 · 1.2y ago
Psoriasis
Ph2 Data
2027-08-21 · 1.4y away
Psoriasis
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04288211 | Phase 2 | Psoriasis | Terminated | 670 | SRI-4 |
| NCT05304450 | Phase 2 | Psoriasis | Completed | 2764 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 |